Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LepVax (Access to Advanced Health Institute, 043181)
- Development stage
- Phase 1
- Lead developer
- Access to Advanced Health Institute
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
LepVax (LEP-F1 + GLA-SE) is a recombinant protein subunit vaccine candidate developed by the Access to Advanced Health Institute (AAHI) for the prevention of leprosy. The vaccine is composed of a fusion protein antigen, LEP-F1, which incorporates four immunodominant proteins from *Mycobacterium leprae* (ML2531, ML2380, ML2055, and ML2028), formulated with the adjuvant GLA-SE (Glucopyranosyl Lipid A in a stable emulsion). GLA-SE acts as a synthetic Toll-like receptor 4 (TLR4) agonist, designed to enhance the induction of a robust Th1-type cellular immune response. This mechanism is intended to provide long-term protection against infection and prevent the development of leprosy-associated nerve damage. LepVax is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and immunogenicity in healthy adults.
- Brand names
- LepVax
- Other names
- LepVaxLEP-F1 + GLA-SE
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on LepVax (Access to Advanced Health Institute, 043181).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LepVax (Access to Advanced Health Institute, 043181).